Press Releases

Hero overlay Cancer research Analyst Coverage Annual Report Proxy Materials Corporate Governance Events Presentations Financial Information Investor Disclaimer Press Releases Stock Information
MENLO PARK, Calif. , Aug. 19, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options covering an aggregate of
August 19, 2022
MENLO PARK, Calif. , Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022 .     Second quarter results Revenue of $35.5 million , a 16% increase compared with $30.6 million in the prior year period.
August 3, 2022
MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of
June 27, 2022

Investor Contact

Pacific Biosciences of California, Inc.
1305 O’Brien Drive, Menlo Park, CA 94025
ir@pacb.com